Five year outcomes of a cohort of HIV-infected injection drug users in a primary care practice

Journal of Addictive Diseases

Volumn 25, Issue 2, 2006, Pages 33-38

  Fingerhood, Michael ^a   Rastegar, Darius A ^a   Jasinski, Donald ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

HAART; HIV infection; Liver disease; Primary care practice

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; BENZODIAZEPINE; COCAINE; DIAMORPHINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABUSE; DRUG OVERDOSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIMARY MEDICAL CARE; TREATMENT OUTCOME; VIRUS LOAD;

ACADEMIC MEDICAL CENTERS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33746640028     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n02_05     Document Type: Article

References (37)

1. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.CMAJ1999;160: 659-665.
2. Loiue JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002;186:1023-1027.
3. Whitman S, J. Murphy, M. Cohen and R. Sherer. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults and injection drug users, from 1995-1997. Arch Intern Med 2000;160:365-369.
4. Mocroft A, Ledergerber B, Katlama C, et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-29.
5. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-1942.
6. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
7. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001;15:423-424.
8. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15:1115-1123.
9. Zaccarelli M, Barracchini A, De Longis P, et al. Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDS 2002;16:67-73.
10. Lucas GM, Cheever LW, Chaisson RE, Moore D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-259.
11. Cohen JA. HIV-1 infection in injection drug users. Infect Dis Clin North Am 2002;16:745-770.
12. Selwyn PA, Alcabes PA, Hartel DM, et al. Clinical manifestations and predictors of disease progression in injecting drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327:1697-1703.
13. Chaisson RE, Keruly JC, Moore RD, Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-756.
14. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-546.
15. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707-1715.
16. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002 Mar 29;16:767-774.
17. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999;22:369-378.
18. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205.
19. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000;14:1229-1235.
20. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003;32:522-526.
21. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003;169:656-661.
22. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med 1992;93:382-386.
23. Rastegar DA, Fingerhood MI, Jasinski DR. Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care 2003;15:231-237.
24. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-950.
25. Romes R, Rumi MG, Donato MF, et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hep 2000;7:297-301.
26. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
27. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207.
28. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of Coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36:363-367.
29. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users. JAMA 1998;279:35-40.
30. Brown LS, Siddiqui NS, Chu AF. Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users. J Natl Med Assoc 1996;88:37-42.
31. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16:1663-1671.
32. Selnes OA, Galai N, McArthur JC, et al. HIV infection and cognition in intravenous drug users: long-term follow-up. Neurology 1997;48:223-230.
33. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999 20;131:81-87.
34. Arici C, Ripamonti D, Ravasio V, Maggiolo F, Rizzi M, Finazzi MG, Suter F. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. Int J STD AIDS 2001;12:573-581.
35. Deeks SG, Hecht FM, Swanson M, et al. (1999). HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13:F35-F43.
36. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004;38 Suppl 5:S409-413.
37. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004;38:S402-408.